$EXEL

Beckerle Mary C sold $527K of EXEL

Beckerle Mary C sold 9,812 shares of EXELIXIS, INC. (EXEL) at $53.66 ($0.53M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Beckerle Mary C
Published Aug 12, 2026, 11:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 11:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EXEL
Neutral
high confidence
Mentioned
$EXEL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; it does not include any new guidance, trial result, deal, or regulatory action.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure and lack of fundamental updates make it unlikely to drive a meaningful repricing by itself.

03

What to watch

The filing does not indicate whether the director’s broader selling program is complete, nor does it provide context on total holdings changes beyond the post-transaction share count.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12 after the 2026-08-10 sale

Background

The article is an SEC Form 4 insider transaction disclosure for EXELIXIS, Inc. (EXEL).

Company-level read

Ticker impact

$EXELNeutralHigh confidence
Context

EXELIXIS director Beckerle Mary C sold 9,812 shares at $53.66 on 2026-08-10 under a 10b5-1 plan, totaling about $526.5K.

Expected impact

Low likelihood of a sustained price move driven by this filing alone.

Evidence & confidence

The disclosure is an open-market sale by a director, explicitly tied to a Rule 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None.

None.

Counterpoint

Insider sales can still reflect private risk perceptions, even when executed under 10b5-1, especially if multiple sales cluster over time.

Key entities

  • EXELIXIS, INC.

    Company whose director insider sale is disclosed on SEC Form 4.

  • Beckerle Mary C

    Director who sold 9,812 shares at $53.66 under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EXELMed

Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?

Exelixis (EXEL) announced a 3-month FDA review extension for zanzalintinib, now targeting March 3, 2027. The FDA requested updated safety and efficacy data. The drug, combined with atezolizumab, aims to treat metastatic colorectal cancer. Exelixis' approval prospects hinge on the full STELLAR-303 study data, which showed a statistically significant survival benefit in the overall population but not in a key subgroup.

$EXELMedAI 8/10

Does Extended FDA Review Change The Bull Case For Exelixis (EXEL)?

Exelixis (EXEL) announced a 3-month FDA review extension for its zanzalintinib plus atezolizumab NDA, moving the decision date to March 3, 2027. The delay is due to updated safety and efficacy data. Analysts highlight the impact on Exelixis' investment narrative, with near-term focus on the colorectal cancer decision. The company aims for $3.3B revenue and $1.3B earnings by 2029, with risks tied to CABOMETYX concentration and margin pressures.

$EXELMed

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Exelixis (EXEL) reported slower-than-expected revenue growth for CABOMETYX due to delayed treatment decisions in NET. The company maintains 47% new-patient market share and plans to launch zanza for colorectal cancer if approved. Exelixis expects CABOMETYX generics in 2031 and is investing in pipeline and share repurchases, with $600M remaining under its authorization.

$EXELLow

FDA Extends Review of Zanzalintinib Combo in Pretreated Metastatic CRC

The FDA extended its review of Exelixis' NDA for zanzalintinib plus atezolizumab to treat metastatic colorectal cancer, moving the PDUFA action date to March 3, 2027. The extension followed updated safety and efficacy data submission, classified as a major amendment. The NDA is supported by the STELLAR-303 trial, which showed a median OS of 10.9 months vs 9.4 months with regorafenib.